Download PDF
Klin Padiatr 2017; 229(05): 281-285
DOI: 10.1055/s-0043-112499
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Palivizumab: The Effects of Prophylactic Immunization on the Occurrence of Infections Caused by the Respiratory Syncytial Virus

Palivizumab: Effekte einer prophylaktischen Immunisierung bei Infektionserscheinungen verursacht durch das Humane Respiratorische Synzytial-Virus
Marjana Jerkovic Raguz
1   NICU Department, Clinic for Children’s Diseases, Sveucilisna Klinicka Bolnica Mostar, Mostar, Bosnia and Herzegovina
,
Jerko Brzica
1   NICU Department, Clinic for Children’s Diseases, Sveucilisna Klinicka Bolnica Mostar, Mostar, Bosnia and Herzegovina
,
Ivana Grgic
2   Clinic of Anesthesiology, Sveucilisna Klinicka Bolnica Mostar, Mostar, Bosnia and Herzegovina
› Author Affiliations
Further Information

Publication History

Publication Date:
25 September 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Aim The aim of this research is to analyze the characteristics of children immunized during immunization season, and their readmission to hospital due to infections of the respiratory tract in the period from 2008 to 2016.

Method The retrospective cohort study included 101 children. The test group consists of infants who met the strict criteria for immunization. The national guidance was determined on the basis of earlier research and recommendations by the AAP. All the children who had been readmitted for hospitalization were quickly tested for RSV.

Results Of this total, 47 children were preterm children (46.5%), 43 (42.5%) were children with CHD, and 11 (11%) exhibited other individual risk factors (gestational age 33–34 weeks, neurological disorders, respiratory anomalies, multi-organ anomalies). 25 (24%) patients of the immunized study population readmitted the ward due to respiratory infections. Of these, 50% were under the age of 6 months and were treated for less than a week on average. Upon readmission, a quick test to diagnose for RSV infections was conducted, which was negative for all of the previously immunized children.

Conclusion Palivizumab represents an effective prevention to avoid RSV infections, that significantly contributes to mortality for children at risk, especially in developing countries.

Zusammenfassung

Ziele In dieser Forschungsarbeit werden die einzelnen Charakteristika von immunisierten Kindern während der RSV-Saison sowie deren erneuten Hospitalisierung infolge von Infektionen des respiratorischen Systems von 2008 bis 2016 analysiert.

Methoden Diese retrospektive Studie umfasst 101 Kinder. Die Testgruppe besteht aus Kindern, die nach strengen Auswahlkriterien rekrutiert wurden. Die nationalen Richtlinien wurden aufgrund von früheren Forschungsergebnissen und Empfehlungen der AAP festgelegt. Alle immunisierten Kinder, die im Krankenhaus erneut behandelt wurden, hatten einen negativen RSV-Schnelltest.

Ergebnisse 47 der rekrutierten Kinder waren Frühgeborene (46,5%), 43 (42,5%) waren Kinder mit angeborenen Herzfehlern, während 11 (11%) sonstige individuelle Risikofaktoren aufzeigten (Schwangerschaftsalter 33–34 Wochen, neurologische Störungen, Anomalien von Atemwegen, Multiorgananomalien). Von der Gesamtzahl der immunisierten Kinder wurden 25 (24%) aufgrund einer Infektion des respiratorischen Systems erneut hospitalisiert. 50% der erneut hospitalisierten Kinder waren jünger als 6 Monate und wurden weniger als eine Woche behandelt. Während der erneuten Hospitalisierung wurde ein Schnelltest zur Diagnose der RSV-Infektion gemacht, der bei allen Patienten negativ war.

Schlussfolgerung Palivizumab ist eine effektive Präventionsmaßnahmezur Vermeidung von RSV-Infektionen, die das Mortalitäts- und Morbiditätsrisiko bei risikogefährdeten Kindern erhöhen. Dies trifft insbesondere für Entwicklungsländer zu.

Key words

immunization - preterm infants - respiratory Syncytial virus - respiratory tract infections

Schlüsselwörter

Immunisierung - Frühgeborene - Das Humane Respiratorische Synzytial-Virus - Infektionen der Atemwege
 

  • References

  • 1 American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn . Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211-1216
    CrossrefPubMedGoogle Scholar
  • 2 American Academy of Pediatrics . Policy statements – Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections Committee on Infectious Diseases. Pediatrics 2009; 124: 1694-1701
    CrossrefPubMedGoogle Scholar
  • 3 Bacharier LB, Cohen R, Schweiger T. et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012; 130: 91-100
    CrossrefPubMedGoogle Scholar
  • 4 Blanken MO, Rovers MM, Molenaar JM. et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368: 1791-1799
    CrossrefPubMedGoogle Scholar
  • 5 Carbonell-Estrany X, Quero J. IRIS Study Group Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001; 20: 874-879
    CrossrefPubMedGoogle Scholar
  • 6 Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003; 88: 1065-1069
    CrossrefPubMedGoogle Scholar
  • 7 Escobar GJ, Ragins A, Li SX. et al. Recurrent wheezing in the third year of life among children born at 32 weeks’ gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life. Arch Pediatr Adolesc Med. 2010; 164: 915-922
    PubMedGoogle Scholar
  • 8 Farber HJ, Buckwold FJ, Lachman B et al. Effectiveness of Palivizumab for 29-36-Week Gestation Infants. Pediatrics 2016; 18:
    PubMed
  • 9 Frogel M, Nerwen C, Cohen A. et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008; 28: 511-517
    CrossrefPubMedGoogle Scholar
  • 10 Griffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017; 30: 277-319
    CrossrefPubMedGoogle Scholar
  • 11 Hall CB, Weinberg GA, Iwane MK. et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360: 588-598
    CrossrefPubMedGoogle Scholar
  • 12 Kristensen K, Hjuler T, Ravn H. et al. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis. 2012; 54: 810-817
    CrossrefPubMedGoogle Scholar
  • 13 Mlinarić Galinović G, Jović M, Knezović I. et al. Epidemiological characteristics of respiratory syncytial virus in 2009 and 2010 in Zagreb and Zagreb County. medicine fulminans 2012; 48: 79-84
    PubMedGoogle Scholar
  • 14 Paes B, Mitchell I, Li A. et al. Respiratory-related hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) compared to other international registries. Clin Dev Immunol. 2013; 917068
    PubMedGoogle Scholar
  • 15 Pedraz C, Carbonell-Estrany X, Figueras-Aloy J. et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003; 22: 823-827
    CrossrefPubMedGoogle Scholar
  • 16 Prais D, Kaplan E, Klinger G. et al. Short- and long-term pulmonary outcome of palivizumab in children born extremely prematurely. Chest 2016; 149: 801-808
    CrossrefPubMedGoogle Scholar
  • 17 Simoes E. Immunoprophylaxis of respiratory syncycal virus: global experience. Respir Res. 202: 26-33
    PubMedGoogle Scholar
  • 18 Vladimir T, Vasily U, Aleksandr G. et al. Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol 2010; 2: 221-227
    PubMedGoogle Scholar
  • 19 Whelan B, Musters E, Murray A. et al. Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. Drugs Ther Perspect 2016; 32: 119-130
    CrossrefPubMedGoogle Scholar
  • 20 Zar HJ, Madhi SA, White DA. et al. Acute viral bronchiolitis in South Africa: Strategies for management and prevention. S Afr Med J. 2016; 106: 27-29
    CrossrefPubMedGoogle Scholar